Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

Abstract

Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients ( P -value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM. Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.

Comprehensive elaboration of circular RNA in multiple myeloma

“…Several tumor markers for combined diagnosis might be an optimized selection for the accurate diagnosis of MM. Gong et al ( Gong et al, 2021 ) discovered that circ_0087776 expression was significantly lower in serum of 136 MM patients compared with 74 healthy controls, with the consistent result in MM cells. Importantly, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, emphasizing that it could be used as a new biomarker for combined diagnosis of MM ( Gong et al, 2021 ).…”

“…Gong et al ( Gong et al, 2021 ) discovered that circ_0087776 expression was significantly lower in serum of 136 MM patients compared with 74 healthy controls, with the consistent result in MM cells. Importantly, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, emphasizing that it could be used as a new biomarker for combined diagnosis of MM ( Gong et al, 2021 ). Altogether, these results verify certain circRNAs as diagnostic and prognostic biomarkers in MM, and further cohort studies are needed to explore more effective biomarkers in the future.…”

“…Through MM cohort study and the xenograft tumor model, Chen et al (Chen et al, 2020b) confirmed that circ-CDYL was elevated in tissue and plasma samples of MM patients; mechanically, circ-CDYL could absorb miR-1180 to upregulate yes-associated protein (YAP) expression, ultimately triggering MM progression. Circ_0000142 was also upregulated in MM patients, and its high expression notably enhanced MM cell proliferation, migration and invasion, while suppressed cell apoptosis (Liu F. et al, 2021). Additionally, circ_0000142 directly targeted miR-610 and positively Frontiers in Pharmacology frontiersin.org regulated AKT3 expression, consequently enhancing the proliferation and metastasis of MM cells (Liu F. et al, 2021).…”

“…Circ_0000142 was also upregulated in MM patients, and its high expression notably enhanced MM cell proliferation, migration and invasion, while suppressed cell apoptosis (Liu F. et al, 2021). Additionally, circ_0000142 directly targeted miR-610 and positively Frontiers in Pharmacology frontiersin.org regulated AKT3 expression, consequently enhancing the proliferation and metastasis of MM cells (Liu F. et al, 2021).…”

Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway

“…First, our study did not include enough clinical samples, and there was a lack of relevant follow-up prognostic information, which made it difficult for us to analyze the correlation between circPOLR2A expression and cRCC prognosis. Due to the stability of circRNAs endowed by their loop structure, several studies have demonstrated the clinical application potential of circRNAs as cancer biomarkers [77,[82][83][84]. Hence, including more cRCC samples with sufficient follow-up data is necessary for evaluating the clinical value of circPOLR2A in future research, which is of great significance for subsequent clinical transformation.…”